A Prescription Drug User Fee Act target date of August 31, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...

Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer's disease, their care partners and healthcare professionals, with ...

Leqembi is currently approved for the treatment of early Alzheimer disease and is administered by IV infusion once every 2 weeks. Findings showed that treatment with the weekly SC formulation resulted ...

TOKYO and CAMBRIDGE, Mass., Aug 4, 2022 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the ...

The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...

STOCKHOLM, April 1, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a supplemental Biologics License Application ...

Clinical trials of lecanemab SC were conducted as a sub-study of the open-label extension (OLE) following the core Phase 3 Clarity AD study in individuals with early AD, to evaluate a range of doses ...

This Phase 1 study was an open-label, parallel-group study conducted in healthy subjects: 30 subjects were randomized into a 10 mg/kg intravenous (IV) dose group and 29 subjects (5 of which were ...

Due to the reaccumulation of AD biomarkers and return to placebo rate of decline after therapy is stopped 1, Eisai is investigating a new lecanemab SC maintenance treatment option following 18 months ...

TOKYO and CAMBRIDGE, Mass., Jul 31, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai")and Biogen Inc. (Nasdaq: BIIB ...